Recent studies have shown that PharmacoGenomic Testing (PGT) can decrease healthcare costs, especially as it involves SAFETY SENSITIVE medications. PGT-led mitigation of risks associated with adverse drug events and serious drug interactions has emerged as a new cost-saving tool for companies.
Improve Safety, Reduce Costs : Poor metabolizers of CYP2D6 or CYP2C19 had 695 more total healthcare visits, >3-fold more medical absence days, 4-fold more disability claims — 2012, University of Illinois Department of Psychiatry - 96 over 1 year
Average Cost to treat patients with extreme phenotypes for CYP2D6 (rapid and poor metabolizers) $400 to $6,000 greater than normal or intermediate metabolizers — 2000, Eastern Tate Hospital in Lexington, 100 patients
82% of American adults take at least one medication daily and 29% take five or more medications daily. (CDC)
Adverse Drug Events (ADE) cause over 700,000 emergency department visits each year. (CDC).
4th leading cause of death, ahead of pulmonary disease, diabetes, AIDS, pneumonia, accidents and automobile deaths (FDA).
$3.5 billion is spent on extra medical costs dues to Adverse Drug Events annually (CDC).
Over 100,000 people die each year due to adverse drug events (FDA).
Ensure that current and future medications are personalized for every employee or patient by contacting Resolve Health today:
Which medications will I learn about from my Resolve Health - IQRx® report?
The chart to the left describes both the genes and the classes of medications that will be described specific to you on you report.
Genetics can affect an individual’s response to medications while in the work place. Pharmacogenomic Testing (PGT) is the study of how a person’s genetic makeup affects that individual’s response to medications. PGT develops a strategy to optimize drug therapies. Test results are used to try and maximize drug efficacy while minimizing adverse drug effects and drug-drug interactions.